Healthcare - Biotechnology - NASDAQ - US
$ 4.41
-8.51 %
$ 235 M
Market Cap
-4.64
P/E
CASH FLOW STATEMENT
-61.4 M
OPERATING CASH FLOW
-60.8 M
INVESTING CASH FLOW
135 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
TScan Therapeutics, Inc.
| Net Income | -89.2 M |
| Depreciation & Amortization | 5.36 M |
| Capital Expenditures | -3.15 M |
| Stock-Based Compensation | 5.21 M |
| Change in Working Capital | 17.6 M |
| Others | 17.3 M |
| Free Cash Flow | -64.5 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (89.2) | (66.2) | (48.6) | (26.1) | (13.7) |
| Depreciation & Amortization | 5.4 | 5.1 | 3.3 | 1.2 | 0.5 |
| Deferred Income Tax | 0 | 0 | (9.2) | 0 | 0 |
| Stock Based Compensation | 5.2 | 4.6 | 2.5 | 0.5 | 0.2 |
| Other Operating Activities | (0.3) | 0.3 | 9.2 | 2 K | 78 K |
| Change in Working Capital | 17.6 | (10.2) | (5.9) | 21.4 | 0.3 |
| Cash From Operations | (61.4) | (66.5) | (48.7) | (3.0) | (12.5) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (3.1) | (4.2) | (9.9) | (4.2) | (1.2) |
| Other Items | (57.6) | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | (60.8) | (4.2) | (9.9) | (4.2) | (1.2) |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 29.4 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 93.0 | (0.2) | 100.0 | 0.3 | 34.8 |
| Cash From Financing Activities | 135.4 | 29.4 | 189.7 | 0.3 | 34.8 |
| CHANGE IN CASH | |||||
| Net Change In Cash | 13.3 | (41.4) | 131.1 | (7.0) | 21.0 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (64.5) | (70.7) | (58.6) | (7.3) | (13.8) |